Functional and anatomical outcomes for intravitreal bevacizumab treatment of choroidal neovascularization in a patient with angioid streaks.
To evaluate the visual and anatomical outcomes of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) treatment of choroidal neovascularization (CNV) in patients with angioid streaks (ASs). A 44-year-old man with angioid streaks and CNV in both eyes (best-corrected visual acuity: 20/400, right eye; 20/50, left eye) received intravitreal bevacizumab injections at monthly intervals. Best-corrected visual acuity in the right eye after 2 intravitreal injections of bevacizumab was 20/70 and remained the same at the 6-month follow-up. Best-corrected visual acuity in the left eye after 3 intravitreal injections of bevacizumab was 20/25 and remained the same at the 9-month follow-up. After intravitreal administration of bevacizumab, our patient had visual acuity improvement in both eyes that was associated with rapid and significant reduction in thickness, subretinal fluid, and size of subfoveal neovascularization secondary to ASs. Intravitreal bevacizumab treatment resulted in a meaningful and sustained vision gain after the 9-months follow-up.